Evaluation of lorlatinib efficacy of patients with EML4-ALK

Not Applicable

Recruiting

• Conditions: ALK positive lung cancer

• Registration Number: JPRN-UMIN000042617
• Lead Sponsor: Japanese Society of Lung Cancer

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-12-02
• Study Completion: 2021-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients from whom written informed consent regarding study participation was not obtained

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response rate (RECIST evaluated by the investigators)